Combination of NKTR-255, a polymer conjugated human IL-15, on efficacy of CAR T cell immunotherapy in a preclinical lymphoma model



Cassie K. Chou^{1,2}, Simon Frassle³, Rachel N. Steinmetz¹, Reed M. Hawkins¹, Tinh-Doan Phi¹, Dirk H. Busch³, Takahiro Miyazaki⁴, Mario Marcondes⁴, Stanley R. Riddell^{1,5}, Cameron J. Turtle^{1,5}

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, ²Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, WA, ³ Technical University of Munich, Munich, Germany, ⁴Nektar Therapeutics, San Francisco, CA, ⁵Department of Medicine, University of Washington, Seattle, WA

Background

mechanisms underlying improved anti-tumor efficacy.

Methods

were euthanized on D8, 11, 14, 21 and 28 post CAR T cell infusion.

Figure 1: CD19 CAR construct





cytometry.

Funding Support

Nektar Therapeutics.